# A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

> **NCT05283837** · PHASE3 · COMPLETED · sponsor: **Zydus Lifesciences Limited** · enrollment: 268 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** Pertuzumab (ZRC-3277)
- **BIOLOGICAL:** Pertuzumab (Perjeta®)

## Key facts

- **NCT ID:** NCT05283837
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-26
- **Primary completion:** 2023-09-06
- **Final completion:** 2023-09-06
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283837, "A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05283837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*